|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:BRAF-CIITA (FusionGDB2 ID:HG673TG4261) |
Fusion Gene Summary for BRAF-CIITA |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: BRAF-CIITA | Fusion gene ID: hg673tg4261 | Hgene | Tgene | Gene symbol | BRAF | CIITA | Gene ID | 673 | 4261 |
| Gene name | B-Raf proto-oncogene, serine/threonine kinase | class II major histocompatibility complex transactivator | |
| Synonyms | B-RAF1|B-raf|BRAF1|NS7|RAFB1 | C2TA|CIITAIV|MHC2TA|NLRA | |
| Cytomap | ('BRAF')('CIITA') 7q34 | 16p13.13 | |
| Type of gene | protein-coding | protein-coding | |
| Description | serine/threonine-protein kinase B-raf94 kDa B-raf proteinB-Raf proto-oncogene serine/threonine-protein kinase (p94)B-Raf serine/threonine-proteinmurine sarcoma viral (v-raf) oncogene homolog B1proto-oncogene B-Rafv-raf murine sarcoma viral oncogene | MHC class II transactivatorMHC class II transactivator type IMHC class II transactivator type IIINLR family, acid domain containingnucleotide-binding oligomerization domain, leucine rich repeat and acid domain containing | |
| Modification date | 20200329 | 20200320 | |
| UniProtAcc | P15056 | . | |
| Ensembl transtripts involved in fusion gene | ENST00000288602, | ||
| Fusion gene scores | * DoF score | 28 X 21 X 11=6468 | 7 X 7 X 6=294 |
| # samples | 32 | 7 | |
| ** MAII score | log2(32/6468*10)=-4.3371758685863 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(7/294*10)=-2.0703893278914 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: BRAF [Title/Abstract] AND CIITA [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | BRAF(140487348)-CIITA(10995371), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | BRAF-CIITA seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. BRAF-CIITA seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. BRAF-CIITA seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. BRAF-CIITA seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | BRAF | GO:0000186 | activation of MAPKK activity | 29433126 |
| Hgene | BRAF | GO:0006468 | protein phosphorylation | 17563371 |
| Hgene | BRAF | GO:0010828 | positive regulation of glucose transmembrane transport | 23010278 |
| Hgene | BRAF | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 19667065 |
| Hgene | BRAF | GO:0043066 | negative regulation of apoptotic process | 19667065 |
| Hgene | BRAF | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 22065586 |
| Hgene | BRAF | GO:0071277 | cellular response to calcium ion | 18567582 |
| Hgene | BRAF | GO:0090150 | establishment of protein localization to membrane | 23010278 |
| Tgene | CIITA | GO:0034341 | response to interferon-gamma | 19041327 |
| Tgene | CIITA | GO:0045345 | positive regulation of MHC class I biosynthetic process | 20639463 |
| Tgene | CIITA | GO:0045892 | negative regulation of transcription, DNA-templated | 19041327 |
| Tgene | CIITA | GO:0045893 | positive regulation of transcription, DNA-templated | 19041327 |
| Tgene | CIITA | GO:0045944 | positive regulation of transcription by RNA polymerase II | 20639463 |
| Tgene | CIITA | GO:0046677 | response to antibiotic | 107465 |
| Fusion gene breakpoints across BRAF (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across CIITA (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | THCA | TCGA-EM-A3AQ-01A | BRAF | chr7 | 140487348 | - | CIITA | chr16 | 10995371 | + |
Top |
Fusion Gene ORF analysis for BRAF-CIITA |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-3UTR | ENST00000288602 | ENST00000537380 | BRAF | chr7 | 140487348 | - | CIITA | chr16 | 10995371 | + |
| In-frame | ENST00000288602 | ENST00000324288 | BRAF | chr7 | 140487348 | - | CIITA | chr16 | 10995371 | + |
| In-frame | ENST00000288602 | ENST00000381835 | BRAF | chr7 | 140487348 | - | CIITA | chr16 | 10995371 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000288602 | BRAF | chr7 | 140487348 | - | ENST00000324288 | CIITA | chr16 | 10995371 | + | 10107 | 1238 | 61 | 4194 | 1377 |
| ENST00000288602 | BRAF | chr7 | 140487348 | - | ENST00000381835 | CIITA | chr16 | 10995371 | + | 3025 | 1238 | 61 | 2442 | 793 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000288602 | ENST00000324288 | BRAF | chr7 | 140487348 | - | CIITA | chr16 | 10995371 | + | 0.001094813 | 0.9989052 |
| ENST00000288602 | ENST00000381835 | BRAF | chr7 | 140487348 | - | CIITA | chr16 | 10995371 | + | 0.006972153 | 0.99302787 |
Top |
Fusion Genomic Features for BRAF-CIITA |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| BRAF | chr7 | 140487347 | - | CIITA | chr16 | 10995370 | + | 3.07E-05 | 0.99996924 |
| BRAF | chr7 | 140487347 | - | CIITA | chr16 | 10995370 | + | 3.07E-05 | 0.99996924 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
 |
Top |
Fusion Protein Features for BRAF-CIITA |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:140487348/chr16:10995371) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| BRAF | . |
| FUNCTION: Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, ECO:0000305}. | FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | BRAF | chr7:140487348 | chr16:10995371 | ENST00000288602 | - | 9 | 18 | 122_129 | 392 | 767.0 | Compositional bias | Note=Poly-Ser |
| Hgene | BRAF | chr7:140487348 | chr16:10995371 | ENST00000288602 | - | 9 | 18 | 6_11 | 392 | 767.0 | Compositional bias | Note=Poly-Gly |
| Hgene | BRAF | chr7:140487348 | chr16:10995371 | ENST00000288602 | - | 9 | 18 | 155_227 | 392 | 767.0 | Domain | RBD |
| Hgene | BRAF | chr7:140487348 | chr16:10995371 | ENST00000288602 | - | 9 | 18 | 234_280 | 392 | 767.0 | Zinc finger | Phorbol-ester/DAG-type |
| Tgene | CIITA | chr7:140487348 | chr16:10995371 | ENST00000324288 | 4 | 20 | 414_724 | 145 | 3032.6666666666665 | Domain | NACHT | |
| Tgene | CIITA | chr7:140487348 | chr16:10995371 | ENST00000324288 | 4 | 20 | 420_427 | 145 | 3032.6666666666665 | Nucleotide binding | Note=GTP | |
| Tgene | CIITA | chr7:140487348 | chr16:10995371 | ENST00000324288 | 4 | 20 | 1016_1037 | 145 | 3032.6666666666665 | Repeat | Note=LRR 2 | |
| Tgene | CIITA | chr7:140487348 | chr16:10995371 | ENST00000324288 | 4 | 20 | 1045_1066 | 145 | 3032.6666666666665 | Repeat | Note=LRR 3 | |
| Tgene | CIITA | chr7:140487348 | chr16:10995371 | ENST00000324288 | 4 | 20 | 1073_1093 | 145 | 3032.6666666666665 | Repeat | Note=LRR 4 | |
| Tgene | CIITA | chr7:140487348 | chr16:10995371 | ENST00000324288 | 4 | 20 | 985_1008 | 145 | 3032.6666666666665 | Repeat | Note=LRR 1 |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | BRAF | chr7:140487348 | chr16:10995371 | ENST00000288602 | - | 9 | 18 | 428_432 | 392 | 767.0 | Compositional bias | Note=Poly-Ser |
| Hgene | BRAF | chr7:140487348 | chr16:10995371 | ENST00000288602 | - | 9 | 18 | 457_717 | 392 | 767.0 | Domain | Protein kinase |
| Hgene | BRAF | chr7:140487348 | chr16:10995371 | ENST00000288602 | - | 9 | 18 | 463_471 | 392 | 767.0 | Nucleotide binding | ATP |
| Tgene | CIITA | chr7:140487348 | chr16:10995371 | ENST00000324288 | 4 | 20 | 52_137 | 145 | 3032.6666666666665 | Compositional bias | Note=Asp/Glu-rich (acidic) | |
| Tgene | CIITA | chr7:140487348 | chr16:10995371 | ENST00000324288 | 4 | 20 | 94_132 | 145 | 3032.6666666666665 | Region | Note=Required for acetyltransferase activity |
Top |
Fusion Gene Sequence for BRAF-CIITA |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >10118_10118_1_BRAF-CIITA_BRAF_chr7_140487348_ENST00000288602_CIITA_chr16_10995371_ENST00000324288_length(transcript)=10107nt_BP=1238nt CGCCTCCCTTCCCCCTCCCCGCCCGACAGCGGCCGCTCGGGCCCCGGCTCTCGGTTATAAGATGGCGGCGCTGAGCGGTGGCGGTGGTGG CGGCGCGGAGCCGGGCCAGGCTCTGTTCAACGGGGACATGGAGCCCGAGGCCGGCGCCGGCGCCGGCGCCGCGGCCTCTTCGGCTGCGGA CCCTGCCATTCCGGAGGAGGTGTGGAATATCAAACAAATGATTAAGTTGACACAGGAACATATAGAGGCCCTATTGGACAAATTTGGTGG GGAGCATAATCCACCATCAATATATCTGGAGGCCTATGAAGAATACACCAGCAAGCTAGATGCACTCCAACAAAGAGAACAACAGTTATT GGAATCTCTGGGGAACGGAACTGATTTTTCTGTTTCTAGCTCTGCATCAATGGATACCGTTACATCTTCTTCCTCTTCTAGCCTTTCAGT GCTACCTTCATCTCTTTCAGTTTTTCAAAATCCCACAGATGTGGCACGGAGCAACCCCAAGTCACCACAAAAACCTATCGTTAGAGTCTT CCTGCCCAACAAACAGAGGACAGTGGTACCTGCAAGGTGTGGAGTTACAGTCCGAGACAGTCTAAAGAAAGCACTGATGATGAGAGGTCT AATCCCAGAGTGCTGTGCTGTTTACAGAATTCAGGATGGAGAGAAGAAACCAATTGGTTGGGACACTGATATTTCCTGGCTTACTGGAGA AGAATTGCATGTGGAAGTGTTGGAGAATGTTCCACTTACAACACACAACTTTGTACGAAAAACGTTTTTCACCTTAGCATTTTGTGACTT TTGTCGAAAGCTGCTTTTCCAGGGTTTCCGCTGTCAAACATGTGGTTATAAATTTCACCAGCGTTGTAGTACAGAAGTTCCACTGATGTG TGTTAATTATGACCAACTTGATTTGCTGTTTGTCTCCAAGTTCTTTGAACACCACCCAATACCACAGGAAGAGGCGTCCTTAGCAGAGAC TGCCCTAACATCTGGATCATCCCCTTCCGCACCCGCCTCGGACTCTATTGGGCCCCAAATTCTCACCAGTCCGTCTCCTTCAAAATCCAT TCCAATTCCACAGCCCTTCCGACCAGCAGATGAAGATCATCGAAATCAATTTGGGCAACGAGACCGATCCTCATCAGCTCCCAATGTGCA TATAAACACAATAGAACCTGTCAATATTGATGACTTGATTAGAGACCAAGGATTTCGTGGTGATGGAGCCTTCCCAGAGGAGCTTCCGGC AGACCTGAAGCACTGGAAGCCAGCTGAGCCCCCCACTGTGGTGACTGGCAGTCTCCTAGTGAGACCAGTGAGCGACTGCTCCACCCTGCC CTGCCTGCCACTGCCTGCGCTGTTCAACCAGGAGCCAGCCTCCGGCCAGATGCGCCTGGAGAAAACCGACCAGATTCCCATGCCTTTCTC CAGTTCCTCGTTGAGCTGCCTGAATCTCCCTGAGGGACCCATCCAGTTTGTCCCCACCATCTCCACTCTGCCCCATGGGCTCTGGCAAAT CTCTGAGGCTGGAACAGGGGTCTCCAGTATATTCATCTACCATGGTGAGGTGCCCCAGGCCAGCCAAGTACCCCCTCCCAGTGGATTCAC TGTCCACGGCCTCCCAACATCTCCAGACCGGCCAGGCTCCACCAGCCCCTTCGCTCCATCAGCCACTGACCTGCCCAGCATGCCTGAACC TGCCCTGACCTCCCGAGCAAACATGACAGAGCACAAGACGTCCCCCACCCAATGCCCGGCAGCTGGAGAGGTCTCCAACAAGCTTCCAAA ATGGCCTGAGCCGGTGGAGCAGTTCTACCGCTCACTGCAGGACACGTATGGTGCCGAGCCCGCAGGCCCGGATGGCATCCTAGTGGAGGT GGATCTGGTGCAGGCCAGGCTGGAGAGGAGCAGCAGCAAGAGCCTGGAGCGGGAACTGGCCACCCCGGACTGGGCAGAACGGCAGCTGGC CCAAGGAGGCCTGGCTGAGGTGCTGTTGGCTGCCAAGGAGCACCGGCGGCCGCGTGAGACACGAGTGATTGCTGTGCTGGGCAAAGCTGG TCAGGGCAAGAGCTATTGGGCTGGGGCAGTGAGCCGGGCCTGGGCTTGTGGCCGGCTTCCCCAGTACGACTTTGTCTTCTCTGTCCCCTG CCATTGCTTGAACCGTCCGGGGGATGCCTATGGCCTGCAGGATCTGCTCTTCTCCCTGGGCCCACAGCCACTCGTGGCGGCCGATGAGGT TTTCAGCCACATCTTGAAGAGACCTGACCGCGTTCTGCTCATCCTAGACGGCTTCGAGGAGCTGGAAGCGCAAGATGGCTTCCTGCACAG CACGTGCGGACCGGCACCGGCGGAGCCCTGCTCCCTCCGGGGGCTGCTGGCCGGCCTTTTCCAGAAGAAGCTGCTCCGAGGTTGCACCCT CCTCCTCACAGCCCGGCCCCGGGGCCGCCTGGTCCAGAGCCTGAGCAAGGCCGACGCCCTATTTGAGCTGTCCGGCTTCTCCATGGAGCA GGCCCAGGCATACGTGATGCGCTACTTTGAGAGCTCAGGGATGACAGAGCACCAAGACAGAGCCCTGACGCTCCTCCGGGACCGGCCACT TCTTCTCAGTCACAGCCACAGCCCTACTTTGTGCCGGGCAGTGTGCCAGCTCTCAGAGGCCCTGCTGGAGCTTGGGGAGGACGCCAAGCT GCCCTCCACGCTCACGGGACTCTATGTCGGCCTGCTGGGCCGTGCAGCCCTCGACAGCCCCCCCGGGGCCCTGGCAGAGCTGGCCAAGCT GGCCTGGGAGCTGGGCCGCAGACATCAAAGTACCCTACAGGAGGACCAGTTCCCATCCGCAGACGTGAGGACCTGGGCGATGGCCAAAGG CTTAGTCCAACACCCACCGCGGGCCGCAGAGTCCGAGCTGGCCTTCCCCAGCTTCCTCCTGCAATGCTTCCTGGGGGCCCTGTGGCTGGC TCTGAGTGGCGAAATCAAGGACAAGGAGCTCCCGCAGTACCTAGCATTGACCCCAAGGAAGAAGAGGCCCTATGACAACTGGCTGGAGGG CGTGCCACGCTTTCTGGCTGGGCTGATCTTCCAGCCTCCCGCCCGCTGCCTGGGAGCCCTACTCGGGCCATCGGCGGCTGCCTCGGTGGA CAGGAAGCAGAAGGTGCTTGCGAGGTACCTGAAGCGGCTGCAGCCGGGGACACTGCGGGCGCGGCAGCTGCTGGAGCTGCTGCACTGCGC CCACGAGGCCGAGGAGGCTGGAATTTGGCAGCACGTGGTACAGGAGCTCCCCGGCCGCCTCTCTTTTCTGGGCACCCGCCTCACGCCTCC TGATGCACATGTACTGGGCAAGGCCTTGGAGGCGGCGGGCCAAGACTTCTCCCTGGACCTCCGCAGCACTGGCATTTGCCCCTCTGGATT GGGGAGCCTCGTGGGACTCAGCTGTGTCACCCGTTTCAGGGCTGCCTTGAGCGACACGGTGGCGCTGTGGGAGTCCCTGCAGCAGCATGG GGAGACCAAGCTACTTCAGGCAGCAGAGGAGAAGTTCACCATCGAGCCTTTCAAAGCCAAGTCCCTGAAGGATGTGGAAGACCTGGGAAA GCTTGTGCAGACTCAGAGGACGAGAAGTTCCTCGGAAGACACAGCTGGGGAGCTCCCTGCTGTTCGGGACCTAAAGAAACTGGAGTTTGC GCTGGGCCCTGTCTCAGGCCCCCAGGCTTTCCCCAAACTGGTGCGGATCCTCACGGCCTTTTCCTCCCTGCAGCATCTGGACCTGGATGC GCTGAGTGAGAACAAGATCGGGGACGAGGGTGTCTCGCAGCTCTCAGCCACCTTCCCCCAGCTGAAGTCCTTGGAAACCCTCAATCTGTC CCAGAACAACATCACTGACCTGGGTGCCTACAAACTCGCCGAGGCCCTGCCTTCGCTCGCTGCATCCCTGCTCAGGCTAAGCTTGTACAA TAACTGCATCTGCGACGTGGGAGCCGAGAGCTTGGCTCGTGTGCTTCCGGACATGGTGTCCCTCCGGGTGATGGACGTCCAGTACAACAA GTTCACGGCTGCCGGGGCCCAGCAGCTCGCTGCCAGCCTTCGGAGGTGTCCTCATGTGGAGACGCTGGCGATGTGGACGCCCACCATCCC ATTCAGTGTCCAGGAACACCTGCAACAACAGGATTCACGGATCAGCCTGAGATGATCCCAGCTGTGCTCTGGACAGGCATGTTCTCTGAG GACACTAACCACGCTGGACCTTGAACTGGGTACTTGTGGACACAGCTCTTCTCCAGGCTGTATCCCATGAGCCTCAGCATCCTGGCACCC GGCCCCTGCTGGTTCAGGGTTGGCCCCTGCCCGGCTGCGGAATGAACCACATCTTGCTCTGCTGACAGACACAGGCCCGGCTCCAGGCTC CTTTAGCGCCCAGTTGGGTGGATGCCTGGTGGCAGCTGCGGTCCACCCAGGAGCCCCGAGGCCTTCTCTGAAGGACATTGCGGACAGCCA CGGCCAGGCCAGAGGGAGTGACAGAGGCAGCCCCATTCTGCCTGCCCAGGCCCCTGCCACCCTGGGGAGAAAGTACTTCTTTTTTTTTAT TTTTAGACAGAGTCTCACTGTTGCCCAGGCTGGCGTGCAGTGGTGCGATCTGGGTTCACTGCAACCTCCGCCTCTTGGGTTCAAGCGATT CTTCTGCTTCAGCCTCCCGAGTAGCTGGGACTACAGGCACCCACCATCATGTCTGGCTAATTTTTCATTTTTAGTAGAGACAGGGTTTTG CCATGTTGGCCAGGCTGGTCTCAAACTCTTGACCTCAGGTGATCCACCCACCTCAGCCTCCCAAAGTGCTGGGATTACAAGCGTGAGCCA CTGCACCGGGCCACAGAGAAAGTACTTCTCCACCCTGCTCTCCGACCAGACACCTTGACAGGGCACACCGGGCACTCAGAAGACACTGAT GGGCAACCCCCAGCCTGCTAATTCCCCAGATTGCAACAGGCTGGGCTTCAGTGGCAGCTGCTTTTGTCTATGGGACTCAATGCACTGACA TTGTTGGCCAAAGCCAAAGCTAGGCCTGGCCAGATGCACCAGCCCTTAGCAGGGAAACAGCTAATGGGACACTAATGGGGCGGTGAGAGG GGAACAGACTGGAAGCACAGCTTCATTTCCTGTGTCTTTTTTCACTACATTATAAATGTCTCTTTAATGTCACAGGCAGGTCCAGGGTTT GAGTTCATACCCTGTTACCATTTTGGGGTACCCACTGCTCTGGTTATCTAATATGTAACAAGCCACCCCAAATCATAGTGGCTTAAAACA ACACTCACATTTATTCTGCTCACATATCTGTCATTTGAGCAGGGCTCAGCGGGGACAGCTCCTTCTGTCCTACTCTGTGTCAGGTGGGGC AGCTTGAGGGTTGGGCTGGTGTCACCTGAAGACTCATTCTTCTGTACGTCTGACAGGCAATGCTGGCTGTTGGCTGGGGGCCTCAGTGCC ACTACGGAATAGTTGGCTAGGACCCCTCCATGTGGGCTAGTTGGGCTTCCTCATAGTATGGTGGCTGGGTTGGAGGGTGTCCCAAAAAGA AAGGAGGGGATAGAGAGAGACCACTTTTCATAACCTAGCCTTAGAAGTCACACAGTATTACTTCTGCTACATATATATGTTTTAAGAGGC AGGGTCTCACTCTGTCGCCCAGTCTGGAATGCAGTGGTATGATCACGGCTCACTGCAGCCTCAACCTCCTGGGCTAAGTGATCCTCCCAC CTCAGCCTCCCGAATAGCTGGGACTACAGGTGTGAGTCACCAAGCCCAGTTAATCTTTAGTTTTATTTTTGTAGAGCCAGGGTCTCACTA TGTTGCCCAGGCAGGTCTTGAACTCCTGGCCTCAAGTGATTCTCCTGCCTCAGCCTCCCAAAGTGCTGGGATTACAGGTGTGAACCACCA CACCCAGCCCACTTCTGCCATATTCTGTTGGCCAGTGTGACAAGGATTGCTACTGTCCTACCCACCCTCCTTTCACCACATGTGCACATG CACGTGTGTGCACGTACACACACATACACACACACGCGTGCACACACCAGAGCCCACCTTGGCTCAAGTCCTCTTTTCTGAGAGGACTTT TCTTTGTGGCTTCCTAAAATTCAGTGGAAAATTAATTGTTTGGGGATGAGAAAGGTTGAAGCACCAAAAGCTTACCAAGGGGAATGTTTG CCTCTGCCTCTGACACACAGCTCTGTCCTGGGAGTGAGCTGGTTTTTAGCGGAGACGGAGTCCCACCTTGGCTGCAGGGAGTCCGAAAGG GACTTGGAAGCTCCGCTTTCTACCCAGCGAGCTGCCGGCACGACTGTTGCTTTTCACTCGGGCATAGTCTGCTCAGAAGCCCCAATTCAA GACATCTTAGCTTACTCCTGGTGGCAGTGGGAGCTGCCTGTTCAGCTCCAGCTCACCAGCCCCAGTGCCCACAGGATCAGTCTGATTCCC AAGCTCTGCTCCTCTCCCCAGCAAGTGAGAGCTGGGTGTCAAGAGGGTCTGAGGAATCCAGACCCGGCTGCGTGGTTGATGATCTTTGCA GACAGGCAAGCACCTCCTGCCTCGAACTGGCTGCAAAGGGTATCAGGTGCTGCCATCCAGGTTCAGCTTGTAAATAGCTCAGGTGTCACC CTGCAAGGGATCCCTGCACTTGCAGACTCTACAGAGGCCATGGGCCTCCTGTGTGTGCGCCTACAGGAGTGAGCACTAAGGTGTGCTCTG ATCATCCACTGTGCCATGTGCCAGGTTTTTGGTCTGACCCACTGCTTTTGGTCTGTGTGATGATGAAATGAGGTCAGAGCCTGCAGTTAT TAACACTAACGATTTGTTAATGATAGCTACTGTTTATTATTTTATTTAATTTTTTTGAGACAGAGTTTTCACTCTTATTGCCCACGCTGG AGTGCAGTGGCATGATCTCGGCTCACTGCAACCTCTGCCTCCTGGGTTCAAGCAATTCTCCCACCTCAGCCTCCCAAGTAGCTGGGATTA CAGGCATGCACCACCACGCCTGGCTAATTTTTGTATTTTTAGTAGAGATGGAGTTTCACCATGTTGGCCAGGCTGGTAATCTGCCTGCCT TGGCCTCCCAAAGTGCTGGGATTACAGGGGTGAGCCACCGCACCCGGCCACTACTGTTTATTTAATGAGCAGATACATGCAAAGCCCTTA TCACAGTGCAAGGGAAATTCAAAGCGCTCAGAAAGTATTAGCTCAATAAGTGATGACTGTGTGCCAGACACTGTGCTAAACTCCTACTCA AGAGGGATAAGAGTCTAGGGGCAAGTGGCAGAGACTCTAGAACGAGATTGCCTGGGCTCAACGCCCACCTCACCACTTACTTATGCAAGC TAGTTCTCTGTGCCTCAGTCTCCTCATTTGTAAAATGGGCATAACCACAGCACCTTCTTTATAGGATTATGTGAAGGTGTGGTGAGCTAA TACGTTAAGAATTGGAGCTCAATAACATGTTGGCTGTCATTATTACATATATCTGTGTTTCATTCTTGCCTCTGGCTGGAATGTTCTTCC CAGCTCTCCATATGGCTGATTTCTCATCCTTCGGGACTTGCCCCATTCTCCAACCCCATCACTAGTTTTATCTTTTTCACTTATTTATGC AGTCTGCTCTTGTCCTAGGACATGAGCTCCAGGAGGGCGGGAAACATCTCGCTTTGTACACTGCTGTGCCCTCTGTACCCAGCAAGGCGC CTGTGTATAATAGGTGCTCAATAACATAAAATGAACAAATAATCCTCACCTAACGGTTTCATTCATTCTGCAAATACATACTGACAGCAC AGTCATGAATAAGATGTTCCTGCCCTGGTGAGTCTTATATTTTAGCAAATTAAAAAAACTCTTTGGACAGGGCTGCCAGGTGAGGTTGGC CAGTCTGTACACTGCACAAAGGCACCTGGGACAAGGGGGAACATGGGGGCTGCAAACCAGTCTGGGTTCTGCTTGCCAAACTGGGAGTCC TGGTGTGGAGCCTTTTAACCCAGAGGGGCATCTTTTCGTAGTTAACGCACAGTCATCGTAAGATGTGGATAAATTACTGTCTCCGTGTCA CAGATCTAAGTGATACTTATAGTCACACTCCTATAAAGGAATGGACTTCTGACTTCTTTGGAGGACCTCTCTGCAGGGACAGGCACAGTG TGCCGGAAGTGCCCCTGAACCCCATTTGTCAGGTGGTAAAGCGCTGCTCGGAGGAATCAGGGCATGATAGTGCAATTCCATGTCCAGTGG ATTGTAAGTCCACGCACCTTCCAAATGGTCACTCTTCCTCGCAGGCCTCTCTCTGCATACAAATGTCTCCCTCCTGACGCTCACCTTTTT CCCTGGGGCTCTCAAATGTCTTCTTTTCAGATTTCGTAGCTTTTCTTTCTTTAGCATCACTTGAGGGCAAGTGGTGCTCCAACTGTCTCC CCCCAGAGTTCTGCCGCCTGTACTCTCCCACACCTCAGTCTCCTCGCCTGTAGAAAGGGGTCAATCGTTTGAACCCTGCTTCACTTGGTG TGTATGTGAAGGTGCTTTGAAATCAAGTGCTCTGCAAACTGGAGAGAATTACTGCTTGTATTCCGTGAAACTACAAGCTCCCAATTCCAC TCATTTAATCCCTCTCTTGCTCTGTTGCCCAGGCTGGAATGCAGTGGCATGATCTCAACTCACTGCAACCTCTGCCTCCCTGGTTTCAAG CAATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGACTATAAGTGTGCGCCACTATGCCTGGCTAATTTTTTTGTATTTTTAGTAGAGATG GGGTTTCACCGTGGTGGCCAGGCTGGTCTCGAACTCCTAACCTCAAGTGATCTGCCCGCCTCGGCCTTCCAAAGTGCTGGGATTACAGGC ATGAGCCACCATGCCAAGCCCTTCCCCCCTATCTTTAATGAAGGTCTACCATGTGCCTGACACAGGGGATACCCACCCCCACTTCTATGG GATTCAGGCCTGGTTTCCAGCTTGGCCTTCAGGCTTTTCCCACCACACCCCAAATGCTGTCCCTGGCTTGTGGAGTGGGGCAGGGGGCCA GCCTGGGACTTTCACGCCAGCCCGACTGGGGCAGACTCTCTCAACCCCACTGGATCTTCTGCTGTTTGTCAGCCACAAGGTTCTGCCTAG AACTCCTTTCCCGAATCTCAAAGTTAAAAAAAAAGGCAGGGCCCCAGGGGTTGGAGTTGCATACATTTTTTTTTAATCCAAAGAAGTAAG CCTCCTAAGTATTGCTTAGACAGGTTTATCAGAATTAAGTAGGCACAACACTCATACTTTCAGAAAAGCATTTCCAGCCAGGGGAGTAAC GTGGCACTCACCAGCATGATGTCTGTTTTGCCAACTTGCTGAAGAACGAGTAACCTGAAATGAAGGAGCGAGAATCCCACCCTCAGCCCC CCAACAGCTTCCTCAGCTTCTTTTTCTTCTGAGTCACCCCTGAAACAGTCGCTGCATCTAAGACCAGCCTCGGGCTAAACCCAGCTGGCC TGAAGGCTCAACTCACATCAAACGGAGCTGGGAGTCGCTTTTGCGTGTGTCCGCAGTTTGAAGTGTCCTCTCCGAAGGTGAAGTGGGGGA AGCAGGTGCGCTCCGGGATGAAGTGCAGGGAGGCAAACTCTGGCTGGGTTCCTGTAAACATCCATCGCAGCTGCAAATAATCAGAAGCCA AGGCCAGGCCATCGATTTGACACTGCAGGCAGATGAGGTCTTGGGATGCCTCTTGCGTTCCCCCTTCTGTGGGAGCAGGTGCCTTCCCAA CCTCAGCACTCAGTCCCAATCTCTCTTCCACTCTCCTGGGTTCAAACAGGAACCTCTCTGTTGGCACGAAGCTTTTGAGGGGAGCAGGTC TAACAAGAAGGAAAAAGGGGGGTTATTAGCACGGAAGCCCCACCCTGCCACCAGGTTGGCTGGGGACAGGGACCAATCCACCAGGCTCGG GAGGCTTGGGGTGGGGCAGGGAAGTCTTCCTCCATCCCTCAAATTTAGGGAACCACTGGGAGCCCCAGACTCAGGCTGAAAATGTCTTTC >10118_10118_1_BRAF-CIITA_BRAF_chr7_140487348_ENST00000288602_CIITA_chr16_10995371_ENST00000324288_length(amino acids)=1377AA_BP=392 MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLD ALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDS LKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQ RCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQR DRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGAFPEELPADLKHWKPAEPPTVVTGSLLVRPVSDCSTLPCLPLPALFNQEPASGQMRLE KTDQIPMPFSSSSLSCLNLPEGPIQFVPTISTLPHGLWQISEAGTGVSSIFIYHGEVPQASQVPPPSGFTVHGLPTSPDRPGSTSPFAPS ATDLPSMPEPALTSRANMTEHKTSPTQCPAAGEVSNKLPKWPEPVEQFYRSLQDTYGAEPAGPDGILVEVDLVQARLERSSSKSLERELA TPDWAERQLAQGGLAEVLLAAKEHRRPRETRVIAVLGKAGQGKSYWAGAVSRAWACGRLPQYDFVFSVPCHCLNRPGDAYGLQDLLFSLG PQPLVAADEVFSHILKRPDRVLLILDGFEELEAQDGFLHSTCGPAPAEPCSLRGLLAGLFQKKLLRGCTLLLTARPRGRLVQSLSKADAL FELSGFSMEQAQAYVMRYFESSGMTEHQDRALTLLRDRPLLLSHSHSPTLCRAVCQLSEALLELGEDAKLPSTLTGLYVGLLGRAALDSP PGALAELAKLAWELGRRHQSTLQEDQFPSADVRTWAMAKGLVQHPPRAAESELAFPSFLLQCFLGALWLALSGEIKDKELPQYLALTPRK KRPYDNWLEGVPRFLAGLIFQPPARCLGALLGPSAAASVDRKQKVLARYLKRLQPGTLRARQLLELLHCAHEAEEAGIWQHVVQELPGRL SFLGTRLTPPDAHVLGKALEAAGQDFSLDLRSTGICPSGLGSLVGLSCVTRFRAALSDTVALWESLQQHGETKLLQAAEEKFTIEPFKAK SLKDVEDLGKLVQTQRTRSSSEDTAGELPAVRDLKKLEFALGPVSGPQAFPKLVRILTAFSSLQHLDLDALSENKIGDEGVSQLSATFPQ LKSLETLNLSQNNITDLGAYKLAEALPSLAASLLRLSLYNNCICDVGAESLARVLPDMVSLRVMDVQYNKFTAAGAQQLAASLRRCPHVE -------------------------------------------------------------- >10118_10118_2_BRAF-CIITA_BRAF_chr7_140487348_ENST00000288602_CIITA_chr16_10995371_ENST00000381835_length(transcript)=3025nt_BP=1238nt CGCCTCCCTTCCCCCTCCCCGCCCGACAGCGGCCGCTCGGGCCCCGGCTCTCGGTTATAAGATGGCGGCGCTGAGCGGTGGCGGTGGTGG CGGCGCGGAGCCGGGCCAGGCTCTGTTCAACGGGGACATGGAGCCCGAGGCCGGCGCCGGCGCCGGCGCCGCGGCCTCTTCGGCTGCGGA CCCTGCCATTCCGGAGGAGGTGTGGAATATCAAACAAATGATTAAGTTGACACAGGAACATATAGAGGCCCTATTGGACAAATTTGGTGG GGAGCATAATCCACCATCAATATATCTGGAGGCCTATGAAGAATACACCAGCAAGCTAGATGCACTCCAACAAAGAGAACAACAGTTATT GGAATCTCTGGGGAACGGAACTGATTTTTCTGTTTCTAGCTCTGCATCAATGGATACCGTTACATCTTCTTCCTCTTCTAGCCTTTCAGT GCTACCTTCATCTCTTTCAGTTTTTCAAAATCCCACAGATGTGGCACGGAGCAACCCCAAGTCACCACAAAAACCTATCGTTAGAGTCTT CCTGCCCAACAAACAGAGGACAGTGGTACCTGCAAGGTGTGGAGTTACAGTCCGAGACAGTCTAAAGAAAGCACTGATGATGAGAGGTCT AATCCCAGAGTGCTGTGCTGTTTACAGAATTCAGGATGGAGAGAAGAAACCAATTGGTTGGGACACTGATATTTCCTGGCTTACTGGAGA AGAATTGCATGTGGAAGTGTTGGAGAATGTTCCACTTACAACACACAACTTTGTACGAAAAACGTTTTTCACCTTAGCATTTTGTGACTT TTGTCGAAAGCTGCTTTTCCAGGGTTTCCGCTGTCAAACATGTGGTTATAAATTTCACCAGCGTTGTAGTACAGAAGTTCCACTGATGTG TGTTAATTATGACCAACTTGATTTGCTGTTTGTCTCCAAGTTCTTTGAACACCACCCAATACCACAGGAAGAGGCGTCCTTAGCAGAGAC TGCCCTAACATCTGGATCATCCCCTTCCGCACCCGCCTCGGACTCTATTGGGCCCCAAATTCTCACCAGTCCGTCTCCTTCAAAATCCAT TCCAATTCCACAGCCCTTCCGACCAGCAGATGAAGATCATCGAAATCAATTTGGGCAACGAGACCGATCCTCATCAGCTCCCAATGTGCA TATAAACACAATAGAACCTGTCAATATTGATGACTTGATTAGAGACCAAGGATTTCGTGGTGATGGAGCCTTCCCAGAGGAGCTTCCGGC AGACCTGAAGCACTGGAAGCCAGTGCCTTTCTCCAGTTCCTCGTTGAGCTGCCTGAATCTCCCTGAGGGACCCATCCAGTTTGTCCCCAC CATCTCCACTCTGCCCCATGGGCTCTGGCAAATCTCTGAGGCTGGAACAGGGGTCTCCAGTATATTCATCTACCATGGTGAGGTGCCCCA GGCCAGCCAAGTACCCCCTCCCAGTGGATTCACTGTCCACGGCCTCCCAACATCTCCAGACCGGCCAGGCTCCACCAGCCCCTTCGCTCC ATCAGCCACTGACCTGCCCAGCATGCCTGAACCTGCCCTGACCTCCCGAGCAAACATGACAGAGCACAAGACGTCCCCCACCCAATGCCC GGCAGCTGGAGAGGTCTCCAACAAGCTTCCAAAATGGCCTGGTCTAGCCTGGTCACCGTGCCTGGGTCTGAGGCCCTCCCTCCACAGGGC TGCCTTGAGCGACACGGTGGCGCTGTGGGAGTCCCTGCAGCAGCATGGGGAGACCAAGCTACTTCAGGCAGCAGAGGAGAAGTTCACCAT CGAGCCTTTCAAAGCCAAGTCCCTGAAGGATGTGGAAGACCTGGGAAAGCTTGTGCAGACTCAGAGGACGAGAAGTTCCTCGGAAGACAC AGCTGGGGAGCTCCCTGCTGTTCGGGACCTAAAGAAACTGGAGTTTGCGCTGGGCCCTGTCTCAGGCCCCCAGGCTTTCCCCAAACTGGT GCGGATCCTCACGGCCTTTTCCTCCCTGCAGCATCTGGACCTGGATGCGCTGAGTGAGAACAAGATCGGGGACGAGGGTGTCTCGCAGCT CTCAGCCACCTTCCCCCAGCTGAAGTCCTTGGAAACCCTCAATCTGTCCCAGAACAACATCACTGACCTGGGTGCCTACAAACTCGCCGA GGCCCTGCCTTCGCTCGCTGCATCCCTGCTCAGGCTAAGCTTGTACAATAACTGCATCTGCGACGTGGGAGCCGAGAGCTTGGCTCGTGT GCTTCCGGACATGGTGTCCCTCCGGGTGATGGACGTCCAGTACAACAAGTTCACGGCTGCCGGGGCCCAGCAGCTCGCTGCCAGCCTTCG GAGGTGTCCTCATGTGGAGACGCTGGCGATGTGGACGCCCACCATCCCATTCAGTGTCCAGGAACACCTGCAACAACAGGATTCACGGAT CAGCCTGAGATGATCCCAGCTGTGCTCTGGACAGGCATGTTCTCTGAGGACACTAACCACGCTGGACCTTGAACTGGGTACTTGTGGACA CAGCTCTTCTCCAGGCTGTATCCCATGAGCCTCAGCATCCTGGCACCCGGCCCCTGCTGGTTCAGGGTTGGCCCCTGCCCGGCTGCGGAA TGAACCACATCTTGCTCTGCTGACAGACACAGGCCCGGCTCCAGGCTCCTTTAGCGCCCAGTTGGGTGGATGCCTGGTGGCAGCTGCGGT CCACCCAGGAGCCCCGAGGCCTTCTCTGAAGGACATTGCGGACAGCCACGGCCAGGCCAGAGGGAGTGACAGAGGCAGCCCCATTCTGCC TGCCCAGGCCCCTGCCACCCTGGGGAGAAAGTACTTCTTTTTTTTTATTTTTAGACAGAGTCTCACTGTTGCCCAGGCTGGCGTGCAGTG GTGCGATCTGGGTTCACTGCAACCTCCGCCTCTTGGGTTCAAGCGATTCTTCTGCTTCAGCCTCCCGAGTAGCTGGGACTACAGGCACCC >10118_10118_2_BRAF-CIITA_BRAF_chr7_140487348_ENST00000288602_CIITA_chr16_10995371_ENST00000381835_length(amino acids)=793AA_BP=392 MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLD ALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDS LKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQ RCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQR DRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGAFPEELPADLKHWKPVPFSSSSLSCLNLPEGPIQFVPTISTLPHGLWQISEAGTGVSS IFIYHGEVPQASQVPPPSGFTVHGLPTSPDRPGSTSPFAPSATDLPSMPEPALTSRANMTEHKTSPTQCPAAGEVSNKLPKWPGLAWSPC LGLRPSLHRAALSDTVALWESLQQHGETKLLQAAEEKFTIEPFKAKSLKDVEDLGKLVQTQRTRSSSEDTAGELPAVRDLKKLEFALGPV SGPQAFPKLVRILTAFSSLQHLDLDALSENKIGDEGVSQLSATFPQLKSLETLNLSQNNITDLGAYKLAEALPSLAASLLRLSLYNNCIC -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for BRAF-CIITA |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for BRAF-CIITA |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | BRAF | P15056 | DB08881 | Vemurafenib | Inhibitor | Small molecule | Approved |
| Hgene | BRAF | P15056 | DB08881 | Vemurafenib | Inhibitor | Small molecule | Approved |
| Hgene | BRAF | P15056 | DB08881 | Vemurafenib | Inhibitor | Small molecule | Approved |
| Hgene | BRAF | P15056 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
| Hgene | BRAF | P15056 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
| Hgene | BRAF | P15056 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
| Hgene | BRAF | P15056 | DB14840 | Ripretinib | Inhibitor | Small molecule | Approved |
| Hgene | BRAF | P15056 | DB14840 | Ripretinib | Inhibitor | Small molecule | Approved |
| Hgene | BRAF | P15056 | DB14840 | Ripretinib | Inhibitor | Small molecule | Approved |
| Hgene | BRAF | P15056 | DB00398 | Sorafenib | Inhibitor | Small molecule | Approved|Investigational |
| Hgene | BRAF | P15056 | DB00398 | Sorafenib | Inhibitor | Small molecule | Approved|Investigational |
| Hgene | BRAF | P15056 | DB00398 | Sorafenib | Inhibitor | Small molecule | Approved|Investigational |
| Hgene | BRAF | P15056 | DB08912 | Dabrafenib | Antagonist|Inhibitor | Small molecule | Approved|Investigational |
| Hgene | BRAF | P15056 | DB08912 | Dabrafenib | Antagonist|Inhibitor | Small molecule | Approved|Investigational |
| Hgene | BRAF | P15056 | DB08912 | Dabrafenib | Antagonist|Inhibitor | Small molecule | Approved|Investigational |
| Hgene | BRAF | P15056 | DB11718 | Encorafenib | Inhibitor | Small molecule | Approved|Investigational |
| Hgene | BRAF | P15056 | DB11718 | Encorafenib | Inhibitor | Small molecule | Approved|Investigational |
| Hgene | BRAF | P15056 | DB11718 | Encorafenib | Inhibitor | Small molecule | Approved|Investigational |
| Hgene | BRAF | P15056 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
| Hgene | BRAF | P15056 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
| Hgene | BRAF | P15056 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for BRAF-CIITA |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | BRAF | C0025202 | melanoma | 24 | CGI;CTD_human;UNIPROT |
| Hgene | BRAF | C1275081 | Cardio-facio-cutaneous syndrome | 14 | CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Hgene | BRAF | C0009402 | Colorectal Carcinoma | 8 | CTD_human;UNIPROT |
| Hgene | BRAF | C0028326 | Noonan Syndrome | 8 | CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET |
| Hgene | BRAF | C0238463 | Papillary thyroid carcinoma | 8 | CTD_human;ORPHANET |
| Hgene | BRAF | C0040136 | Thyroid Neoplasm | 6 | CGI;CTD_human |
| Hgene | BRAF | C0151468 | Thyroid Gland Follicular Adenoma | 6 | CTD_human |
| Hgene | BRAF | C0175704 | LEOPARD Syndrome | 6 | CLINGEN;GENOMICS_ENGLAND |
| Hgene | BRAF | C0549473 | Thyroid carcinoma | 6 | CGI;CTD_human |
| Hgene | BRAF | C3150970 | NOONAN SYNDROME 7 | 5 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Hgene | BRAF | C0009404 | Colorectal Neoplasms | 4 | CTD_human |
| Hgene | BRAF | C3150971 | LEOPARD SYNDROME 3 | 4 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Hgene | BRAF | C1519086 | Pilomyxoid astrocytoma | 3 | ORPHANET |
| Hgene | BRAF | C0004565 | Melanoma, B16 | 2 | CTD_human |
| Hgene | BRAF | C0009075 | Melanoma, Cloudman S91 | 2 | CTD_human |
| Hgene | BRAF | C0018598 | Melanoma, Harding-Passey | 2 | CTD_human |
| Hgene | BRAF | C0023443 | Hairy Cell Leukemia | 2 | CGI;ORPHANET |
| Hgene | BRAF | C0025205 | Melanoma, Experimental | 2 | CTD_human |
| Hgene | BRAF | C0033578 | Prostatic Neoplasms | 2 | CTD_human |
| Hgene | BRAF | C0152013 | Adenocarcinoma of lung (disorder) | 2 | CGI;CTD_human |
| Hgene | BRAF | C0376358 | Malignant neoplasm of prostate | 2 | CTD_human |
| Hgene | BRAF | C0587248 | Costello syndrome (disorder) | 2 | CLINGEN;CTD_human |
| Hgene | BRAF | C3501843 | Nonmedullary Thyroid Carcinoma | 2 | CTD_human |
| Hgene | BRAF | C3501844 | Familial Nonmedullary Thyroid Cancer | 2 | CTD_human |
| Hgene | BRAF | C0002448 | Ameloblastoma | 1 | CTD_human |
| Hgene | BRAF | C0004114 | Astrocytoma | 1 | CTD_human |
| Hgene | BRAF | C0010276 | Craniopharyngioma | 1 | CTD_human;ORPHANET |
| Hgene | BRAF | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human |
| Hgene | BRAF | C0017638 | Glioma | 1 | CGI;CTD_human |
| Hgene | BRAF | C0019621 | Histiocytosis, Langerhans-Cell | 1 | CGI;ORPHANET |
| Hgene | BRAF | C0022665 | Kidney Neoplasm | 1 | CTD_human |
| Hgene | BRAF | C0023903 | Liver neoplasms | 1 | CTD_human |
| Hgene | BRAF | C0024232 | Lymphatic Metastasis | 1 | CTD_human |
| Hgene | BRAF | C0024694 | Mandibular Neoplasms | 1 | CTD_human |
| Hgene | BRAF | C0027659 | Neoplasms, Experimental | 1 | CTD_human |
| Hgene | BRAF | C0027962 | Melanocytic nevus | 1 | GENOMICS_ENGLAND |
| Hgene | BRAF | C0036920 | Sezary Syndrome | 1 | CTD_human |
| Hgene | BRAF | C0041409 | Turner Syndrome, Male | 1 | CTD_human |
| Hgene | BRAF | C0079773 | Lymphoma, T-Cell, Cutaneous | 1 | CTD_human |
| Hgene | BRAF | C0205768 | Subependymal Giant Cell Astrocytoma | 1 | CTD_human |
| Hgene | BRAF | C0206686 | Adrenocortical carcinoma | 1 | CTD_human |
| Hgene | BRAF | C0206754 | Neuroendocrine Tumors | 1 | CTD_human |
| Hgene | BRAF | C0259783 | mixed gliomas | 1 | CTD_human |
| Hgene | BRAF | C0278875 | Adult Craniopharyngioma | 1 | CTD_human |
| Hgene | BRAF | C0280783 | Juvenile Pilocytic Astrocytoma | 1 | CTD_human |
| Hgene | BRAF | C0280785 | Diffuse Astrocytoma | 1 | CTD_human |
| Hgene | BRAF | C0334579 | Anaplastic astrocytoma | 1 | CGI;CTD_human |
| Hgene | BRAF | C0334580 | Protoplasmic astrocytoma | 1 | CTD_human |
| Hgene | BRAF | C0334581 | Gemistocytic astrocytoma | 1 | CTD_human |
| Hgene | BRAF | C0334582 | Fibrillary Astrocytoma | 1 | CTD_human |
| Hgene | BRAF | C0334583 | Pilocytic Astrocytoma | 1 | CGI;CTD_human |
| Hgene | BRAF | C0338070 | Childhood Cerebral Astrocytoma | 1 | CTD_human |
| Hgene | BRAF | C0345904 | Malignant neoplasm of liver | 1 | CTD_human |
| Hgene | BRAF | C0376407 | Granulomatous Slack Skin | 1 | CTD_human |
| Hgene | BRAF | C0406803 | Syringocystadenoma Papilliferum | 1 | GENOMICS_ENGLAND |
| Hgene | BRAF | C0431128 | Papillary craniopharyngioma | 1 | CTD_human |
| Hgene | BRAF | C0431129 | Adamantinous Craniopharyngioma | 1 | CTD_human |
| Hgene | BRAF | C0547065 | Mixed oligoastrocytoma | 1 | CTD_human |
| Hgene | BRAF | C0555198 | Malignant Glioma | 1 | CTD_human |
| Hgene | BRAF | C0596263 | Carcinogenesis | 1 | CTD_human |
| Hgene | BRAF | C0684249 | Carcinoma of lung | 1 | CGI;UNIPROT |
| Hgene | BRAF | C0740457 | Malignant neoplasm of kidney | 1 | CTD_human |
| Hgene | BRAF | C0750935 | Cerebral Astrocytoma | 1 | CTD_human |
| Hgene | BRAF | C0750936 | Intracranial Astrocytoma | 1 | CTD_human |
| Hgene | BRAF | C0751061 | Craniopharyngioma, Child | 1 | CTD_human |
| Hgene | BRAF | C0920269 | Microsatellite Instability | 1 | CTD_human |
| Hgene | BRAF | C1527404 | Female Pseudo-Turner Syndrome | 1 | CTD_human |
| Hgene | BRAF | C1704230 | Grade I Astrocytoma | 1 | CTD_human |
| Hgene | BRAF | C1721098 | Replication Error Phenotype | 1 | CTD_human |
| Hgene | BRAF | C2239176 | Liver carcinoma | 1 | CTD_human |
| Hgene | BRAF | C4551484 | Leopard Syndrome 1 | 1 | GENOMICS_ENGLAND |
| Hgene | BRAF | C4551602 | Noonan Syndrome 1 | 1 | CTD_human |
| Hgene | BRAF | C4721532 | Lymphoma, Non-Hodgkin, Familial | 1 | UNIPROT |
| Hgene | BRAF | C4733333 | familial non-medullary thyroid cancer | 1 | GENOMICS_ENGLAND |
| Tgene | C2931418 | Bare lymphocyte syndrome 2 | 5 | CTD_human;ORPHANET;UNIPROT | |
| Tgene | C0001403 | Addison Disease | 1 | CTD_human | |
| Tgene | C1859534 | Bare Lymphocyte Syndrome, Type II, Complementation Group A | 1 | GENOMICS_ENGLAND | |
| Tgene | C2930967 | Gastro-enteropancreatic neuroendocrine tumor | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies